CAS: 228113-66-4; 1-(4-((4-((4R,5R)-3,3-Dibutyl-7-(Dimethylamino)-4-Hydroxy-1,1-Dioxido-2,3,4,5-Tetrahydrobenzo[b]Thiepin-5-yl)Phenoxy)Methyl)Benzyl)-1,4-Diazabicyclo[2.2.2]Octan-1-Ium Chloride
该化合物是一种依赖钠的胆碱酸运输器(ASBT)抑制剂,主要用于治疗患有拉吉综合症(ALGS)和累进家庭内血清胆碱酯酶(PICT)的病人的胆固磷. 它通过有选择地阻塞ile酸再吸附于ileum,减少了系统的二氧化酸积聚,从而减轻了酸,提高了生活质量.它的口服管理提供了一种非外科的替代方法,如血清转移等程序. 临床研究表明,它能有效降低血清胆碱酸水平和症状严重程度,并具有可控制的安全性. 马拉西克氯化物是稀有胆碱性肝紊乱的一种有针对性的治疗选择.
- 英文名称1-(4-((4-((4R,5R)-3,3-Dibutyl-7-(Dimethylamino)-4-Hydroxy-1,1-Dioxido-2,3,4,5-Tetrahydrobenzo[b]Thiepin-5-yl)Phenoxy)Methyl)Benzyl)-1,4-Diazabicyclo[2.2.2]Octan-1-Ium Chloride
- 中文名称氯马昔巴特
- IUPAC名称1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium chloride
- 其它别名Maralixibat Chloride; Maralixibat Chloride [inn]; Livmarli; Cloruro De Maralixibat; Unii-V78M04F0Xc; (4R,5R)-5-[4-[[4-(4-Aza-1-Azoniabicyclo[2.2.2]Octan-1-Ylmethyl)Phenyl]Methoxy]Phenyl]-3,3-Dibutyl-7-(Dimethylamino)
- CAS编号228113-66-4
- MFCD编号:MFCD28502264
- FDA UNII编号:V78M04F0XC
- 分子式:C40H56ClN3O4S分子量:710.42
- 产品CID: 1167418
- 同类组份化合物CAS228113-66-4 (chloride)716313-53-0 (cation)Maralixibat bromideMaralixibat chloride hydrate
- 产品分类有机原料 → 有机杂环化合物 → 苯并硫平类
物理性质
MSDS等安全信息
合成工艺路线路线简述
📜(4R,5R)-3,3-Dibutyl-5-[4-[[4-(Chloromethyl)Phenyl]Methoxy]Phenyl]-7-(Dimethylamino)-1,1-Dioxo-4,5-Dihydro-2H-1Lambda6-Benzothiepin-4-Ol,三乙烯二胺 以 乙腈 用作溶剂,化学反应 2.0H,反应生成氯马昔巴特
参考文献:Method Of Preparing Enantiomerically-Enriched Tetrahydrobenzothiepine Oxides
标题:Method Of Preparing Enantiomerically-Enriched Tetrahydrobenzothiepine Oxides
摘要:一种制备对映富集的四氢苯并噻吩氧化物的过程,包括环化对映富集的芳基-3-丙醛亚磺酸盐,其中芳基-3-丙醛亚磺酸盐的硫原子是手性中心.
海关参考信息
- 2902600000-乙苯
2905122000-异丙醇
2906210000-苄醇
2921211000-乙二胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Kohut TJ, Gilbert MA, Loomes KM. Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment. Semin Liver Dis. 2021 Jul 2. doi: 10.1055/s-0041-1730951. Epub ahead of print. Childhood Liver Disease Research Network (ChiLDReN). Mutation Analysis and Disease Features at Presentation in a Multi-Center Cohort of Children With Monogenic Cholestasis. J Pediatr Gastroenterol Nutr. 2021 Aug 1;73(2):169-177. doi: 10.1097/MPG.0000000000003153.
3: Burns J, Davenport M. Adjuvant treatments for biliary atresia. Transl Pediatr. 2020 Jun;9(3):253-265. doi: 10.21037/tp.2016.10.08.
4: Karpen SJ, Kelly D, Mack C, Stein P. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689. doi: 10.1007/s12072-020-10070-w. Epub 2020 Jul 11. Childhood Liver Disease Research Network (ChiLDReN). Unraveling the Relationship Between Itching, Scratch Scales, and Biomarkers in Children With Alagille Syndrome. Hepatol Commun. 2020 May 26;4(7):1012-1018. doi: 10.1002/hep4.1522.
合成参考文献
摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2022)
📝 需求与反馈
尽可能描述清楚需求与问题信息
